Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Withdrawal, Double-blind, Placebo-controlled, Multi-center Study Investigating The Efficacy And Safety Of Pf-04965842 In Subjects Aged 12 Years And Over, With Moderate To Severe Atopic Dermatitis With The Option Of Rescue Treatment In Flaring Subjects

Trial Profile

A Phase 3 Randomized Withdrawal, Double-blind, Placebo-controlled, Multi-center Study Investigating The Efficacy And Safety Of Pf-04965842 In Subjects Aged 12 Years And Over, With Moderate To Severe Atopic Dermatitis With The Option Of Rescue Treatment In Flaring Subjects

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Abrocitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Aug 2018 Planned End Date changed from 2 Jul 2020 to 3 Jul 2020.
    • 16 Aug 2018 Planned primary completion date changed from 2 Jul 2020 to 3 Jul 2020.
    • 11 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top